Sleep and Medicinal Cannabis

INVESTIGATOR: Sean Drummond, Ph.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: Sleep and Medicinal Cannabis

PROJECT TYPE: Clinical Study, Sub-Study

STATUS: COMPLETE

ABSTRACT:

Recently, there has been renewed scientific interest in examining the medical efficacy of cannabis in specific patient populations. For, example, both the Institute of Medicine and the NIH recently reported medicinal cannabis might be useful in the treatment of pain in HIV+ patients. HIV+ patients experience a number of clinical sequelae to the infection, even when they are otherwise considered clinically "asymptomatic." Perhaps one of the earliest sequelae is sleep abnormality. It is estimated that 73% to 90% of HIV+ patients experience significantly disrupted sleep and sleep quality has been shown to predict long-term outcome in HIV+ patients. This study examines the effects of daytime medicinal cannabis administration on subsequent nocturnal subjective and objective measures of sleep in patients with HIV-associated DSPN. We will recruit 15 patients who are enrolled in a study currently funded by the CMCR (PI: Dr. Ellis; Award # C00-SD-104). Dr. Ellis' study examines the efficacy of medicinal cannabis vs. placebo in treating pain in patients with HIV-associated DSPN. Here, subjective sleep will be measured for three 1-week periods: a wash-in week, a week of cannabis administration, and a week of placebo administration. Objective sleep will be studied for two consecutive nights under both cannabis administration and placebo conditions. We hypothesize that, compared to placebo, cannabis will increase slow wave sleep and sleep efficiency and decrease REM sleep. Subjectively, patients will report increased global sleep quality, decreased sleep latency, and increased total sleep time with cannabis administration. If these hypotheses are borne out, it will provide evidence that cannabis has positive medicinal qualities beyond those formally suggested. Improved sleep may directly affect prognosis in these patients and may have several indirect benefits as well. Regardless, this study should provide pilot data for subsequent grant applications focusing on the direct effects of medicinal cannabis on sleep in patient populations.

PUBLICATIONS:

Type:

Title:

Meeting Abstract Lopez, C., Toperoff, W., van den Brande, G., Tapert, S., Atkinson, J.H., Drummond, S.P.A., Increased Sleep Disturbances in Patients with HIV-Related Neuropathy. 2005 Annual Meeting of the Associated Professional Sleep Societies.

Funding Opportunity Announcement

The Center for Medicinal Cannabis Research (CMCR) is seeking to fund primary and pilot cannabis-related studies that further enhance the understanding of the efficacy and adverse effects of cannabis and cannabinoids as pharmacological agents for the treatment of medical and psychiatric disorders, and their potential public health impacts. More information about this funding opportunity, including application instructions and important dates can be found in the request for applications (RFA).


No, CBD-infused jelly beans won’t get you high. Here’s why.

Eli Rosenberg, Washington Post, March 19, 2019

There is CBD beer, and CBD coffee, and CBD gummies and soda, skin care, oils and drops. And now the cannabis-derived product is appearing in jelly beans — designed by the man who created Jelly Belly candies.

The product, a mash-up of an “adult” chemical compound — CBD — and a staple of American childhoods, has been so popular that the company that created it, Spectrum Confections, helmed by Jelly Belly inventor David Klein, sold out after a spate of press coverage over the past week.

“Jelly Belly creator debuts cannabis-infused jelly beans: Toasted marshmallow, mango and more,” USA Today wrote.

Read the story here


Can CBD Help Your Child?

Rachel Rabkin Peachman, Consumer Reports, February 26, 2019

When a child is sick and conventional medicine isn’t helping, parents understandably often turn to alternative treatments. Recently, that includes cannabidiol, aka CBD, which is a cannabis compound found in marijuana and hemp that’s being touted as a remedy for everything from pain and arthritis to seizures and sleep problems. Unlike the cannabis plant’s other well-known compound, THC (tetrahydrocannabinol), CBD does not get users high, it’s nonaddictive, and it has a low risk of side effects—which makes it seem like an appealing option for children.

While CBD is being used widely by adults, the best evidence for it comes from studies focusing on children with certain kinds of epilepsy. And increasingly, parents are giving CBD to their children to manage a range of other conditions, such as autism and anxiety.

Read the article here


New Study Analyzes Cost Effectiveness of Smoked Cannabis to Treat Chronic Neuropathic Pain

Kathryn Ryan, Mary Ann Liebert, Inc., January 29, 2019

Smoked cannabis as an adjunctive second-line therapy to treat chronic peripheral neuropathy can be both effective and cost-effective. The results of a new study simulating its use in one million patients are published in Cannabis and Cannabinoid Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Cannabis and Cannabinoid Research website.

In the article entitled “A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain,” David Grelotti, MD, University of California San Diego (La Jolla) and coauthors from UCSD, University of California Center for Medicinal Cannabis Research (San Diego), and Columbia University (New York, NY) created a computer simulation to compare the cost of usual first-, second-, and third-line care with those supplemented with smoked cannabis. They modeled efficacy and adverse events based on clinical trial and other existing study data, and derived cannabis cost from retail market pricing.

Read the full press release here


Smoking weed: When is someone too high to drive?

NBC News, January 3, 2019

It used to be the stuff of stoner comedies and “Just Say No” campaigns. Today, marijuana is becoming mainstream as voters across the country approve ballot questions for legalization or medical use.

In response, state governments are testing ways to ensure that the integration of this once-illicit substance into everyday life doesn’t create new public health risks. These efforts are sparking a difficult question: At what point is someone too high to get behind the wheel?

The answer is complicated. Brain scientists and pharmacologists don’t know how to measure if and to what extent marijuana causes impairment.

Read the rest of the story here


Igor Grant, MD

Marijuana as Medicine: Can We See Past the Smoke?
North American Cannabis Summit presentation January 2019 (PDF)


Igor Grant, MD

Introduction/Overview
CMCR Symposium, June 2018


Daniele Piomelli, MD, PhD, PharmD

The health impact of cannabis
CMCR Symposium, June 2018


Ziva Cooper, PhD

Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018


Iain McGregor, PhD

Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018


Thomas Marcotte, PhD

Cannabis and public safety: The challenge of cannabis-impaired driving
CMCR Symposium, June 2018


Ryan Vandrey, PhD

What's in real-world cannabis?
CMCR Symposium, June 2018


Copyright © 2019 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego
cmcr@ucsd.edu | HNRP |